A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2004
12/23/2004	WO2004110419A1 Agonist agents and medicinal compositions
12/23/2004	WO2004110417A2 Compositions for the enhanced treatment of depression
12/23/2004	WO2004110416A2 Use of a cx3c agonist for the treatment of pain and for promoting nerve regeneration
12/23/2004	WO2004110415A2 Substituted 1, 4-di-piperidin-4-yl-piperazine derivative combined with an opioid analgesic and their use for the treatment of pain and side-effects associated with opioid-based treatments
12/23/2004	WO2004110410A1 Extended release composition containing tramadol
12/23/2004	WO2004110409A1 Pharmaceutical compositions comprising atorvastatin manufactured without granulation
12/23/2004	WO2004110408A2 Process for the manufacture of stable shaped particles consisting of estradiol and cholesterol
12/23/2004	WO2004110407A1 Process for forming amorphous atorvastatin
12/23/2004	WO2004110406A1 Pharmaceutical compositions of atorvastatin
12/23/2004	WO2004110402A1 Oil emulsion for postnatal hormone substitution
12/23/2004	WO2004110400A2 Implantable polymeric device for sustained release of nalmefene
12/23/2004	WO2004110399A2 Solvates of cefprozil
12/23/2004	WO2004110398A1 Pharmaceutical composition in the form of a gel or a solution based on dihydrotestosterone, process for preparing it and uses thereof
12/23/2004	WO2004110392A2 Compositions and methods for treating coronavirus infection and sars
12/23/2004	WO2004110389A2 Sigma ligands for neuronal regeneration and functional recovery
12/23/2004	WO2004110388A2 Sigma ligands for neuronal regeneration and functional recovery
12/23/2004	WO2004110387A2 Sigma ligands for neuronal regeneration and functional recovery
12/23/2004	WO2004110383A2 Pharmaceutical composition and method for alleviating side effects of estrogen replacement therapy
12/23/2004	WO2004110381A2 Pharmaceutical compositions comprising active vitamin d compounds
12/23/2004	WO2004110380A2 Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
12/23/2004	WO2004110379A2 A1 adenosine receptor antagonists
12/23/2004	WO2004110378A2 Treatment alzheimer's disease with r(-) 2-arylproponic acid nsaid alone or in combination with selective cox-2 inhibitor
12/23/2004	WO2004110377A2 Porphyrins and metalloporphyrins for inhibiting heme iron uptake
12/23/2004	WO2004110376A2 Ccr-2 antagonists for treatment of neuropathic pain
12/23/2004	WO2004110375A2 Combination therapy for the treatment of diabetes
12/23/2004	WO2004110374A2 3,4-disubstituted benzamidines and benzylamines, and analogues thereof, useful as serine protease inhibitors
12/23/2004	WO2004110371A2 Method for the treatment of malignancies
12/23/2004	WO2004110361A2 Anticancer compositions comprising methenamine
12/23/2004	WO2004110360A2 Proteoglycan degrading mutants for treatment of cns
12/23/2004	WO2004110359A2 Fusion proteins for the treatment of cns
12/23/2004	WO2004110357A2 Heterocyclic compounds and uses thereof
12/23/2004	WO2004110355A2 Compositions and methods including a recombinant human mab that promotes cns remyelination
12/23/2004	WO2004110354A2 Method for reducing amyloid deposition, amyloid neurotoxicity and microgliosis
12/23/2004	WO2004110352A2 Compounds having activity in increasing ion transport by mutant-cftr and uses thereof
12/23/2004	WO2004110351A2 Heterocyclic compounds for treating hepatitis c virus
12/23/2004	WO2004110350A2 Compouds and uses thereof in modulating amyloid beta
12/23/2004	WO2004110348A2 Saururus cernuus compounds that inhibit cellular responses to hypoxia
12/23/2004	WO2004110347A2 Compositions and methods for reducing scar tissue formation
12/23/2004	WO2004110346A2 Sustained release of antiinfectives
12/23/2004	WO2004110344A2 New azetidine compounds
12/23/2004	WO2004110339A2 Method for selective targeting of apoptotic cells and small molecule ligands used thereof
12/23/2004	WO2004110338A2 Methods of treating obesity and related disorders using tellurium and selenium compounds
12/23/2004	WO2004110255A2 Antineoplastic agents targeted via glut transporters
12/23/2004	WO2004110245A2 Combination therapy for cancer treatment
12/23/2004	WO2004110178A1 Hot liquid fiber product
12/23/2004	WO2004110174A1 Composition and foods for lowering glycemic index
12/23/2004	WO2004110153A1 Agents against microorganisms, containing patchouli oil, patchouli alcohol and/or the derivatives thereof
12/23/2004	WO2004110151A1 Treatment of cancer with active vitamin d compounds in combination with radiotherapeutic agents and treatments
12/23/2004	WO2004110149A1 Use of isoindolinone derivatives as insecticides
12/23/2004	WO2004099150A3 3-(1-naphthyl)-2-cyanopropanoic acid derivatives as estrogen receptor ligands
12/23/2004	WO2004098566A3 Chewable lozenge cold remedy composition and method for making same
12/23/2004	WO2004096125A3 Pharmaceutical compositions releasing their active agents from a buccal or sublingual location to overcome an absorption window problem
12/23/2004	WO2004094451A3 8&dollar;G(B)-VINYL-11&dollar;G(B)-(&dollar;G(V)-SUBSTITUTED)ALKYL-ESTRA-1,3,5(10)-TRIENES
12/23/2004	WO2004093852A3 Use of steroid derivatives for the treatment of angiotensin ii related disease e.g. cardiovascular and proliferative disorders
12/23/2004	WO2004091482A3 M3 muscarinic acetylcholine receptor antagonists
12/23/2004	WO2004089917A3 Process for resolving 2,4-diamino-3,6-dihydro-1,3,5-triazines, useful for the treatment of disorders associated with insulin resistance syndrome
12/23/2004	WO2004089908A3 3-azabicyclo[3.2.1]octane derivatives
12/23/2004	WO2004089471A3 NEW PYRAZOLO[1,5-a] PYRIMIDINES DERIVATIVES AND PHARMACEUTICAL USE THEREOF
12/23/2004	WO2004089470A3 New amide derivatives and pharmaceutical use thereof
12/23/2004	WO2004089380A3 Pharmaceutical use of fused 1,2,4-triazoles
12/23/2004	WO2004087203A3 Immunostimulatory nucleic acid oil-in-water formulations for topical application
12/23/2004	WO2004087121A3 Water soluble formulations of digitalis glycosides for treating cell-proliferative and other diseases
12/23/2004	WO2004087048A3 Benzamide modulators of metabotropic glutamate receptors
12/23/2004	WO2004084881B1 METHODS FOR TREATING FUNCTIONAL BOWEL DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS
12/23/2004	WO2004084876A3 Use of compounds for the prevention of drug-induced cell toxicity
12/23/2004	WO2004083215A9 Nitrogeneous polycyclic derivatives useful as chelators of metal ions and their applications
12/23/2004	WO2004083171A3 Use of pyridin-2-ylmethylamine derivatives for the treatment of chronic neuropathological or psychogenic pain symptoms
12/23/2004	WO2004082674A9 Carnitine retention
12/23/2004	WO2004082588A3 Dispersible formulation of an anti-inflammatory agent
12/23/2004	WO2004082586A3 Phamaceutical compositions comprising inhibitors of fab i and further antibiotics
12/23/2004	WO2004078142A3 Compositions and methods for preventing and treating endotoxin-related diseases and conditions
12/23/2004	WO2004078128A3 Substituted pyridine derivatives useful in the treatment of cancer and other disorders
12/23/2004	WO2004076411A3 Aminocyclopentyl fused heterotricylicamide modulators of chemokine receptor activity
12/23/2004	WO2004074270A3 Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
12/23/2004	WO2004073599A3 Inhibitors of hepatitis c virus, compositions and treatments using the same
12/23/2004	WO2004073375A3 Podophyllotoxin derivatives as antitumor agents
12/23/2004	WO2004071447A3 Substituted azole derivatives as therapeutic agents
12/23/2004	WO2004071390A3 Piperazine-2-carboxamide derivatives
12/23/2004	WO2004069141B1 Transdermal granisetron
12/23/2004	WO2004064843A3 Compound preparation for dizziness
12/23/2004	WO2004064836A3 Treatment of diseases with alpha-7 nach receptor full agonists
12/23/2004	WO2004064715A3 Polyhydroxylated pyrrolizidine
12/23/2004	WO2004056317A3 Compositions for the treatment and prevention of nephropathy
12/23/2004	WO2004054497A3 Use of a trpm8-activating substance for the treatment of tumours
12/23/2004	WO2004049095A3 Betaine and salicylic acid compositions
12/23/2004	WO2004045563A3 Method of treatment of myocardial infarction
12/23/2004	WO2004042002A3 Compounds for modulating rna interference
12/23/2004	WO2004041189A3 A method for inhibiting cancer development by fatty acid synthase inhibitors
12/23/2004	WO2004037199A3 Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
12/23/2004	WO2004032823A3 Treatment and rehydration composition which is used to limit the side effects of gastro-enteritis in adults
12/23/2004	WO2004022123A8 Coated stent
12/23/2004	WO2004009062A3 NMDA RECEPTOR ANTAGONISTS AND THEIR USE IN INHIBITING ABNORMAL HYPERPHOSPHORYLATION OF MICROTUBULE ASSOCIATED PROTEIN tau
12/23/2004	WO2003101995A8 Camptothecins with a modified lactone ring
12/23/2004	WO2003101497A8 Knockout mice and their use
12/23/2004	WO2003097805A3 Delivery of nucleic acid-like compounds
12/23/2004	WO2003095438A9 Substituted phenylacetamides and their use as glucokinase activators
12/23/2004	WO2003082198A3 Methods of treatment with lxr modulators
12/23/2004	WO2003080081A3 Synergistic composition of trans-tetracos-15-enoic acid and apocynin and use thereof
12/23/2004	US20040260268 Drug/drug delivery systems for the prevention and treatment of vascular disease
12/23/2004	US20040260267 Expanded clitoral sensitizing compounds with methods and apparatus for the delivery of these compounds

1 ... 4847 4848 4849 4850 4851 4852 4853 4854 4855 4856 4857 4858 4859 4860 4861 4862 4863 4864 4865 4866 4867 ... 7860